RESUMEN
Ketorolac tromethamine 0.5% ophthalmic solution treatment was compared to placebo treatment in 120 patients with chronic aphakic or pseudophakic cystoid macular edema (six-month or more duration of distance visual acuity of 20/40 or less and angiographic evidence of cystoid changes) during a four- to five-month double-masked, multicenter study in which patients were randomly assigned. A statistically significant improvement in distance visual acuity (two lines or more) was observed in the ketorolac-treated group as compared to the placebo-treated group after 30 days (P = .038), 60 days (P = .017), and 90 days (P = .008) of treatment. This improvement in visual acuity remained statistically significant one month after cessation of treatment (P = .001). Nine ketorolac-treated patients and two placebo-treated patients demonstrated a decrease in visual acuity one month after treatment was discontinued. Seven of the nine ketorolac-treated patients experienced an improvement in visual acuity after retreatment as compared to none of the placebo-treated patients. This study offers evidence for a more optimistic outlook in the medical treatment of chronic aphakic and pseudophakic cystoid macular edema.
Asunto(s)
Afaquia/tratamiento farmacológico , Edema Macular/tratamiento farmacológico , Tolmetina/análogos & derivados , Trometamina/uso terapéutico , Agudeza Visual , Administración Tópica , Antiinflamatorios no Esteroideos/uso terapéutico , Afaquia/fisiopatología , Enfermedad Crónica , Método Doble Ciego , Combinación de Medicamentos , Oftalmopatías/inducido químicamente , Humanos , Ketorolaco Trometamina , Edema Macular/fisiopatología , Tolmetina/efectos adversos , Tolmetina/uso terapéutico , Trometamina/efectos adversosRESUMEN
Of 18 mentally retarded institutionalized subjects who had received long-term, high-dose treatment primarily with thioridazine or chlorpromazine, 2 developed definite corneal and lenticular opacities and 2 had equivocal ocular changes. In view of this finding, the authors suggest that alternative treatment, including different neuroleptics, be considered with mentally retarded institutionalized subjects; when that is not possible, subjects should be given periodic evaluation, including annual slit-lamp examination.